Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bilastine - FAES Farma

Drug Profile

Bilastine - FAES Farma

Alternative Names: Aligrin; Bellozal; Bilador; Bilahist; Bilanoa; Bilaska; Bilaxten; Bilaz; Bilidren; BLEXTEN; Borenar; Clatra; Drynol; F-96221-BM; Fortecal; Gosall; Ibis; Ilaxten; Inorial; Labixten; Lamiastine; Lendin; Lergonix; Nasitop; Nixar; Obalix; Olisir; Omarit; Opexa; Revitelle; Robilas; TAC-202; Vitador; Xados; Zilas

Latest Information Update: 16 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FAES Farma
  • Developer Aralez Pharmaceuticals Inc.; FAES Farma; Menarini; Menarini Asia-Pacific; Taiho Pharmaceutical; Yuhan
  • Class Antiallergics; Antihistamines; Benzimidazoles; Eye disorder therapies; Piperidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic conjunctivitis; Perennial allergic rhinitis; Pruritus; Seasonal allergic rhinitis; Urticaria
  • Phase III Allergic rhinoconjunctivitis
  • Phase I Unspecified
  • Discontinued Angioedema

Most Recent Events

  • 31 Dec 2018 Nuvo Pharmaceuticals in-licenses Bilastine from Aralez Pharmaceuticals
  • 26 Sep 2018 Phase-III clinical trials in Allergic conjunctivitis in Lithuania (Ophthalmic) (EudraCT2018-002248-95)
  • 19 Sep 2018 Nuvo Pharmaceuticals and Aralez Pharmaceuticals enter into a purchase agreement
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top